Kallikrein
KLK; Kallikrein-related peptidase
Kallikrein is a serine protease that plays a crucial role in the kallikrein-kinin system. Plasma kallikrein, specifically expressed in hepatocytes, acts on high molecular weight kininogen to release bradykinin, which is involved in regulating vascular tone, inflammatory response, and endogenous blood coagulation and fibrinolysis. Tissue kallikrein, widely distributed in various tissues such as the lung, kidney, and brain, acts on low molecular weight kininogen to produce kinin, participating in processes like blood pressure regulation, electrolyte balance, and neuronal protection. Additionally, kallikrein can bind to LDLR, promoting its lysosomal degradation, and interact with ASICs to affect neuronal function in the central nervous system. Dysregulation of kallikrein activity is associated with various diseases including heart disease, kidney disease, and cancer[1][2].
References:
- [1]. Raspi G. Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods. J Chromatogr B Biomed Appl. 1996 Sep 20;684(1-2):265-87. [Content Brief]
- [2]. Yousef GM, et al. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001 Apr;22(2):184-204. [Content Brief]
Kallikrein Isoform Specific Products
All Product Categories
-
Kallikrein Related Products (64)
Related Products (64)
-
Antibodies (4)
-
Kallikrein Isoform Comparison
-
KVD-001
0 ImagesKVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research.
-
LM-030
0 ImagesCat. No.: HY-P4669CAS No.: 1122484-55-2Synonyms: BPR277LM-030 (BPR277), cyclic depsipeptide, is a potent kallikrein-related peptidase 7 (KLK7) and human neutrophil elastase inhibitor with IC50 values of 1 and 10 nM. LM-030 can be used for the study of Netherton syndrome.
-
Eflumenibep alfa
0 ImagesCat. No.: HY-P991676CAS No.: 2418159-10-9Synonyms: DS-2325AEflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus.
-
Donidalorsen sodium
0 ImagesCat. No.: HY-139787ACAS No.: 2304701-45-7Synonyms: ISIS-721744; IONIS-PKK-LRXDonidalorsen (ISIS-721744; IONIS-PKK-LRX) sodium is an antisense oligonucleotide targeting prekallikrein (PKK). Donidalorsen sodium inhibits kallikrein activity and reduces the production of Bradykinin (HY-P0206) by specifically binding to and degrading PKK mRNA in the liver. Donidalorsen sodium can be used in the research of hereditary angioedema.
-
DKFZ-251
0 ImagesCat. No.: HY-124714CAS No.: 2222059-70-1DKFZ-251 is a kininogenase-related peptidase KLK6 inhibitor (IC50=0.47 μM), and also exhibits certain inhibitory activity against KLK5 and KLK7 (IC50 values are 1.1 nM and 73 nM, respectively). DKFZ-251 transiently acylates the catalytic serine of KLK6 to form a long-lived acyl-enzyme complex that inhibits enzyme function. DKFZ-251 is a phenotypic modulator that alters cell proliferation capacity and regulates epithelial-mesenchymal transition (EMT). DKFZ-251 can be used in research related to head and neck cancer.
-
Anti-KLK5/Kallikrein 5 Antibody
0 ImagesCat. No.: HY-P990459Purity: 98.49%Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
-
KLK6-IN-2
0 ImagesCat. No.: HY-189095CAS No.: 57323-76-9KLK6-IN-2 is a reversible non-covalent and selective KLK6 inhibitor, with an IC50 of 2.1 μM against hKLK6. KLK6-IN-2 acts as a reversible competitive inhibitor of boar Spermatozoa acrosin, with a Ki of 2.6 μM against porcine acrosin. KLK6-IN-2 exhibits trypanocidal activity against Trypanosoma brucei rhodesiense, with an IC50 of 3.71 μM.
-
Plasma kallikrein-IN-1
0 ImagesCat. No.: HY-139888CAS No.: 2691030-28-9Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.
-
FE-999024
0 ImagesCat. No.: HY-117478CAS No.: 168825-65-8Synonyms: CH-2856FE-999024 (CH-2856) is a specific tissue kallikrein inhibitor. FE-999024 can inhibit cancer cells invasion with a maximum of 39%. FE-999024 can reduce eosinophilia in a model of allergic inflammation. FE-999024 can be used for the researches of cancer, inflammation and immunology.
-
Anti-KLK7 Antibody
0 ImagesCat. No.: HY-P992250
-
Donidalorsen sodium scrambled negative control
0 ImagesCat. No.: HY-139787CDonidalorsen sodium scrambled negative control is the sequence scrambled negative control of Donidalorsen sodium (HY-139787A).
-
DKFZ-633
0 ImagesCat. No.: HY-124610CAS No.: 2244425-14-5DKFZ-633 is a potent KLK6 inhibitor and KLK6-specific probe with an IC50 of 250 nM against human KLK6. DKFZ-633 covalently labels active KLK6 in a specific manner, and successfully pulls down and captures endogenous active KLK6 from cell-conditioned media. DKFZ-633 serves as a critical tool for investigating the function of KLK6 and its regulatory mechanisms in head and neck cancer.
-
KLK5-IN-1
0 ImagesCat. No.: HY-P11840KLK5-IN-1 is a selective kallikrein 5 (KLK5) inhibitor with an IC50 of 14 nM and a Ki of 11 nM. KLK5-IN-1 reduces KLK5-mediated PAR2-dependent calcium mobilization. KLK5-IN-1 improves epithelial barrier integrity. KLK5-IN-1 can be used in research related to atopic dermatitis and Netherton syndrome.
-
KLK7-IN-1
0 ImagesCat. No.: HY-W556970CAS No.: 63124-11-8KLK7-IN-1 is a KLK7 inhibitor with an IC50 of 43.3 μM. KLK7-IN-1 is used in studies of kallikrein-driven pathologies.
-
pKal-IN-1
0 ImagesCat. No.: HY-181798CAS No.: 2773609-90-6pKal-IN-1 (compound 13) is a plasma kallikrein (pKal) inhibitor. pKal-IN-1 can be used for the research of diabetic macular edema, diabetic retinopathy.
-
DPC423
0 ImagesCat. No.: HY-11090ACAS No.: 292135-59-2DPC423 is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis.
-
Ecallantide
0 ImagesCat. No.: HY-108814CAS No.: 460738-38-9Synonyms: DX-88Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
-
PPACK II
0 ImagesCat. No.: HY-122543ACAS No.: 74392-49-7PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor.
-
GSK951
0 ImagesCat. No.: HY-150085CAS No.: 2393881-77-9GSK951 is a highly potent, selective, and reversibly covalent KLK5 inhibitor, with an IC50 of approximately 250 pM and a pIC50 of 9.6 against hKLK5. It exhibits over 100-fold selectivity over KLK7, KLK14, matriptase, and elastase. GSK951 binds to the catalytic site of KLK5 via covalent interaction with the catalytic serine, with a slow dissociation rate. GSK951 improves skin barrier function, reduces transepidermal water loss, decreases the expression of proinflammatory cytokines, and inhibits the elevated KLK5 protease activity in the stratum corneum. GSK951 can be used in studies related to skin barrier dysfunction.
-
Onvuzosiran sodium
0 ImagesCat. No.: HY-177652AOnvuzosiran sodium, a siRNA, is a prekallikrein synthesis reducer.
